title: [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part I. Ticlopidine].
abstract: In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives. In the first communication pharmacodynamics and pharmacokinetics of the first thienopyridine ticlopidine are described in detail. Results of randomized studies in which cerebro and cardioprotective efficacy and safety of ticlopidine was studied in patients with cerebrovascular, peripheral artery diseases, and acute coronary syndromes are discussed. It has been established that ticlopidine is more effective and safe in patients having undergone coronary and femoral bypass surgery. Results of meta analyses have shown which evidence that ticlopidine is not less and may be more effective than clopidogrel in patients after coronary bypass surgery. Most frequent and most severe side effects of ticlopidine and measures of their prevention are also considered.
authors.forename: D V
authors.initials: DV
authors.lastname: Fettser
authors.forename: D V
authors.initials: DV
authors.lastname: Preobrazhenskiĭ
authors.forename: T A
authors.initials: TA
authors.lastname: Batyraliev
authors.forename: B A
authors.initials: BA
authors.lastname: Sidorenko
authors.forename: S A
authors.initials: SA
authors.lastname: Pataraia
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D013988:Ticlopidine / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; C446540:thienopyridine; D013988:Ticlopidine